Plasma and Platelet microRNAs in Clopidogrel Low Response Patients
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Clopidogrel is an important anti-platelet agent.However, about 30% of the coronary artery
disease patients presented clopidogrel low response (CLR).Previous studies showed that the
cardiovascular event ratio of the CLR patients was 4.4 times of the normal responders.
It is known that the plasma and platelet miRNAs are determined by different disease status
when platelets are released from the megakaryocyte, and the platelet miRNAs can adjust the
expressions of the platelet's receptors and proteins.The purpose of this study is to find
multiple platelet miRNAs involved in the development of CLR, and platelet miRNAs cause CLR
through adjusting the expressions of the key receptors and proteins in the ADP activating
pathway and consequently reducing their responses to clopidogrel.
The CLR will be detected by light transmission aggregometry (LTA) and vasodilator-stimulated
phosphoprotein phosphorylation (VASP-P). Differential expressions of plasma and platelet
miRNAs profile in CLR patients will be screened by deep sequencing and validated to
investigate the association between plasma and platelet miRNAs profile and CLR as well as the
patients' prognosis.The study results would serve as markers for individualized anti-platelet
treatment, and supply new targets for the treatment of coronary artery disease.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University